BCR-ABL kinase domain mutations and clonal evolution as major causes of resistance to targeted therapy in chronic myelogenous leukemia

被引：0
|
作者：
Andrikovics, H.
Meggyesi, N.
Lueff, S.
Batai, A.
Adam, E.
Kozma, A.
Halm, G.
Nahajevszky, S.
Kapas, B.
Csukly, Z.
Lovas, N.
Remenyi, P.
Tordai, A.
Masszi, T.
机构：
[1] Natl Med Ctr, Dept Mol Diagnost, Budapest, Hungary
[2] Natl Med Ctr, Dept Hematol & Stem Transplantat, Budapest, Hungary
来源：
BLOOD REVIEWS | 2007年 / 21卷
关键词：
D O I：
10.1016/S0268-960X(07)70054-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 50 条
  • [1] BCR-ABL kinase domain mutations in chronic myeloid leukemia - Not quite enough to cause resistance to imatinib therapy?
    Lange, T
    Park, B
    Willis, SG
    Deininger, MWN
    CELL CYCLE, 2005, 4 (12) : 1761 - 1766
  • [2] Imatinib resistance in chronic myelogenous leukemia is frequently associated with either ABL kinase mutations or with secondary rearrangements of the BCR-ABL
    Yin, C
    Luthra, R
    Cortes, J
    Reeves, N
    Hayes, K
    Glassman, A
    Kantarjian, H
    Jones, D
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2004, 6 (04): : 416 - 416
  • [3] Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
    O'Hare, Thomas
    Eide, Christopher A.
    Deininger, Michael W. N.
    BLOOD, 2007, 110 (07) : 2242 - 2249
  • [4] BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
    Schiffer, Charles A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 258 - 265
  • [5] BCR-ABL TYROSINE KINASE DOMAIN MUTATIONS COMBINATIONS AFFECTS IMATINIB RESISTENCE IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
    Bintoro, S. U. Y.
    Amrita, P. N. A.
    Joewarini, E.
    Suryohusodo, P.
    Soebandiri, S.
    NEW ARMENIAN MEDICAL JOURNAL, 2019, 13 (04): : 53 - 58
  • [6] Induction of BCR-ABL mutations for acquired resistance in chronic myelogenous leukemia cells by imatinib
    Yuan, Hongfeng
    Gao, Chunggang
    Bhatia, Ravi
    Chen, WenYong
    CANCER RESEARCH, 2009, 69
  • [7] Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
    Yap, E.
    Tumian, N. R.
    Azma, R. Z.
    Sharifah, N. A.
    Salwati, S.
    Hamidah, N. H.
    Elias, M. H.
    Wong, C. L.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) : 107 - 113
  • [8] HIGH RESOLUTION MELTING ANALYSIS FOR RAPID DETECTION OF BCR-ABL KINASE DOMAIN MUTATIONS IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WITH IMATINIB RESISTANCE
    Andrikovics, H.
    Meggyesi, N.
    Bors, A.
    Halm, G.
    Nahajevszky, S.
    Lueff, S.
    Batai, A.
    Remenyi, P.
    Masszi, T.
    Tordai, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 490 - 490
  • [9] Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia
    O'Dwyer, ME
    Druker, BJ
    CURRENT OPINION IN ONCOLOGY, 2000, 12 (06) : 594 - 597
  • [10] THE BCR-ABL GENE IN CHRONIC MYELOGENOUS LEUKEMIA
    SAWYERS, CL
    CANCER SURVEYS, 1992, 15 : 37 - 51
12345